Paper - WANFANG MED ONLINE

You Position: Home > Paper

Cytokine Therapy for Melanoma

( views:215, downloads:34 )

Author:: No author available

Journal Title:: INTERNATIONAL JOURNAL OF DERMATOLOGY AND VENEREOLOGY

Issue:: 5

DOI:: 10.3760/cma.j.issn.1673-4173.2006.05.006

Key Word:: 黑色素瘤;细胞因子类;治疗

Abstract：免疫治疗已成为恶性黑素瘤的疗法之一,包括单克隆抗体、细胞因子、肿瘤疫苗等多种方法.其中细胞因子治疗黑素瘤的作用近年来倍受人们关注.就各种细胞因子如白介素、干扰素、肿瘤坏死因子、集落刺激因子治疗黑素瘤的研究进展做一综述,提示细胞因子及其联合疗法在治疗黑素瘤作用中的重要地位.

Reference

[1]John M, Kirkwood,Thomas, Richards,Hassane M, Zarour,etc.Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690.[J].2002,95.
[2]Chandrakala, Menon,Malini, Iyer,Indira, Prabakaran,etc.TNF-alpha downregulates vascular endothelial Flk-1 expression in human melanoma xenograft model.[J].2003,284.
[3]Gollob J. A..Phase I Trial of Concurrent Twice-Weekly Recombinant Human Interleukin-12 Plus Low-Dose IL-2 in Patients With Melanoma or Renal Cell Carcinoma[J].2003.
[4]Parrish-Novak Julia,Dillon Stacey R.,Nelson Andrew,etc.Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function[J].2000,408(6808).
[5]B, Guillot,P, Portalès,A Du, Thanh,etc.The expression of cytotoxic mediators is altered in mononuclear cells of patients with melanoma and increased by interferon-alpha treatment.[J].2005,152.
[6]Stoitchkov K,Sales F,Eggermont AM,etc.Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.[J].2005,366(9492).
[7]Steven J, O'Day,Peter D, Boasberg,Lawrence, Piro,etc.Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy.[J].2002,8.
[8]Muggiano A,Fiori B,Pintus M,etc.Feasibility of high-dose interferon-alpha2b adjuvant therapy for high-risk resected cutaneous melanoma.[J].2004,14(2).
[9]Gang, Wang,Mary, Tschoi,Rosanne, Spolski,etc.In vivo antitumor activity of interleukin 21 mediated by natural killer cells.[J].2003,63.
[10]Alatrash G..Clinical and Immunologic Effects of Subcutaneously Administered Interleukin-12 and Interferon Alfa-2b: Phase I Trial of Patients With Metastatic Renal Cell Carcinoma or Malignant Melanoma[J].2004.
[11]Omar Eton,Michael G. Rosenblum,Sewa S. Legha,etc.Phase I trial of subcutaneous recombinant human interleukin‐2 in patients with metastatic melanoma[J].2002,95(1).
[12]Finkelstein SE,Lichtman MK,Klebanoff CA,etc.IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8(+) T Cells[J].2004,101(7).
[13]R, Mortarini,A, Borri,G, Tragni,etc.Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+ T cells in melanoma patients receiving interleukin 12.[J].2000,60.
[14]Bernard A. Fox,Hong-Ming Hu,Jane Yamada,etc.TNF Plays an Essential Role in Tumor Regression after Adoptive Transfer of Perforin/IFN-gamma Double Knockout Effector T Cells[J].2003,170(4).
[15]Konz RF,Grusby MJ,Whitters MJ,etc.IL-21 Activates Both Innate and Adaptive Immunity to Generate Potent Antitumor Responses that Require Perforin but Are Independent of IFN-gamma.[J].2003,171(2).
[16]J A, Gollob,J W, Mier,K, Veenstra,etc.Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response.[J].2000,6.
[17]William E.Carson,Gregory B.Lesinski,Tim Crespin,etc.IL-12 Pretreatments Enhance IFN-alpha-Induced Janus Kinase-STAT Signaling and Potentiate the Antitumor Effects of IFN-alpha in a Murine Model of Malignant Melanoma[J].2004,172(12).